What is the 13F Pro Quality Score for SIGA?

13F Pro ranks SIGA TECHNOLOGIES INC (SIGA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SIGA's current score at https://13fpro.ai/research/SIGA (free sign-up required for the full ranking).

Which hedge funds own the most SIGA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SIGA include BlackRock,, DIMENSIONAL FUND ADVISORS, AltraVue Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SIGA as soon as new 13F filings post.

Where does 13F Pro source SIGA data?

All SIGA TECHNOLOGIES INC fundamentals and ownership data come directly from SEC EDGAR. SIGA TECHNOLOGIES INC files with the SEC under CIK 1010086. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SIGA in?

SIGA TECHNOLOGIES INC (SIGA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are SIGA's largest expenses?

SIGA TECHNOLOGIES INC's latest 10-Q reports these as the largest expense items: Selling, general and administrative ($4.7M, -17% YoY); Research and development ($3.9M, +14% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (three months ended March 31, 2026).

How often is SIGA research updated on 13F Pro?

SIGA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SIGA TECHNOLOGIES INC(SIGA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1010086 SIGA stock profile & AI dashboard →

13F Pro Quality Score

73.6/100

Rank #190 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.7/100

Profitability

90.5/100

Balance Sheet

89.2/100

Earnings Quality

92.7/100

Free Cash Flow

93.2/100

Institutional Flow

26.3/100

Revenue Scale

17.3/100

Dilution Risk

29.4/100

SIGA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SIGA TECHNOLOGIES INC (SIGA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SIGA at 73.6/100 on a 32-signal composite quality model, placing it at rank #190 of 2,879 stocks — the top 10% of the AI-ranked universe. SIGA scores in the top quartile across free cash flow (93.2), earnings quality (92.7), revenue growth (90.7). Areas of concern include revenue scale (17.3) and institutional flow (26.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SIGA TECHNOLOGIES INC reports quarterly revenue of $6.2M, net income of $-3.5M, free cash flow of $-8.7M. Top institutional holders of SIGA by reported 13-F value include BlackRock,, DIMENSIONAL FUND ADVISORS, AltraVue Capital,, based on the most recent SEC filings. SIGA trades on the Nasdaq exchange and files with the SEC under CIK 1010086. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SIGA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SIGA TECHNOLOGIES INC directly from SEC EDGAR. SIGA TECHNOLOGIES INC's 13F Pro composite quality score has ranged between 36 and 76 since 2021, currently 73.6 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about SIGA TECHNOLOGIES INC

Quirks, history, and lore behind SIGA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in New York City.
2
The Numbers
Annual revenue in the range of tens of millions of dollars, almost entirely dependent on a single product and government procurement contracts.
3
The History
Founded in the late 1990s, the company spent years in development before landing a drug approval tied to one of the most feared bioterrorism threats on the planet.
4
The Secret
Its primary customer isn't a hospital chain or pharmacy — it's the U.S. federal government, which stockpiles its drug in the Strategic National Stockpile.
5
The Lore
When monkeypox outbreaks spike anywhere in the world, this company's stock price tends to spike right along with them — investors treat it as a biodefense barometer.
6
The Giveaway
Its flagship drug TPOXX (tecovirimat) is the only FDA-approved oral treatment for smallpox — a disease officially eradicated, yet still worth defending against.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving SIGA's Business? Latest 10-Q Breakdown

AI-extracted from SIGA TECHNOLOGIES INC's 10-Q filed 2026-05-07 — Q1 2026 (three months ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Largest Expense Items

Selling, general and administrative$4.7M-17% YoY

Decrease reflects lower professional service fees and lower international business development expenses, partially offset by higher compensation costs.

Research and development$3.9M+14% YoY

Increase primarily attributable to costs incurred in connection with the EMA referral procedure focused on mpox.

Watch Items from the Filing

EMA referral procedure initiated July 2024 concluded March 2026 with recommendation to remove mpox indication from Tecovirimat-SIGA; label now covers smallpox, cowpox, and vaccinia only, eliminating a key regulatory approval.
19C BARDA Contract represents $630M total contemplated payments (as of March 31, 2026), of which $545.2M relates to exercised options and $5.6M to unexercised options at BARDA's sole discretion; $450.2M of oral TPOXX cumulative deliveries completed.
No international sales in Q1 2026 versus $5.8M in Q1 2025; Meridian International Promotion Agreement expires May 31, 2026 with no automatic renewal; new MENA license agreement with Hikma entered March 2026.
Cash declined $9.4M in Q1 2026 from operating activities; company paid special dividend of $0.60 per share ($43.9M total) in April 2026, reducing liquidity to $145.6M as of quarter-end.
Three mpox clinical trials (PALM 007, STOMP, UNITY) failed primary endpoints; TPOXX showed no statistically significant improvement in time to lesion resolution versus placebo, though safety profile remained comparable.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$6.2M

Net Income

Q1 2026

$-3.5M

Free Cash Flow

Q1 2026

$-8.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.9% YoY

$138.7MFY 2024

FY21 $133.7MFY22 $110.8MFY23 $139.9MFY24 $138.7M

Net Income

-13.0% YoY

$59.2MFY 2024

FY21 $69.5MFY22 $33.9MFY23 $68.1MFY24 $59.2M

Operating Income

-16.3% YoY

$70.0MFY 2024

FY21 $89.1MFY22 $42.7MFY23 $83.6MFY24 $70.0M

EPS (Diluted)

-13.7% YoY

$0.82FY 2024

FY21 $0.91FY22 $0.46FY23 $0.95FY24 $0.82

Total Assets

-3.9% YoY

$244.3MFY 2024

FY21 $214.7MFY22 $195.0MFY23 $254.4MFY24 $244.3M

Total Debt

—FY 2024

FY21 —FY22 —FY23 —FY24 —

Op. Cash Flow

-48.6% YoY

$48.8MFY 2024

FY21 $11.5MFY22 $41.6MFY23 $94.8MFY24 $48.8M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$138.7M -0.9%	$139.9M +26.3%	$110.8M -17.1%	$133.7M +7.0%	$125.0M +367.3%	$26.7M
Net Income	$59.2M -13.0%	$68.1M +100.8%	$33.9M -51.2%	$69.5M +23.3%	$56.3M +878.1%	$-7.2M
Operating Income	$70.0M -16.3%	$83.6M +95.8%	$42.7M -52.1%	$89.1M +5.4%	$84.5M +3738.9%	$-2.3M
EPS (Diluted)	$0.82 -13.7%	$0.95 +106.5%	$0.46 -49.5%	$0.91 +28.2%	$0.71 +573.3%	$-0.15
Total Assets	$244.3M -3.9%	$254.4M +30.4%	$195.0M -9.2%	$214.7M +43.3%	$149.8M -24.5%	$198.6M
Total Debt	—	—	—	—	$0.00 -100.0%	$80.0M
Operating Cash Flow	$48.8M -48.6%	$94.8M +127.8%	$41.6M +262.0%	$11.5M -83.9%	$71.5M +492.9%	$-18.2M

AI Insight: SIGA Financial Trends

SIGA's revenue shows extreme quarterly volatility with $81M spikes in Q4 2024 and Q2 2025, but underlying trend deteriorated with four consecutive quarters of operating losses.

• Revenue swung from $81M in Q2 2025 to just $3M in Q3 2025, highlighting extreme quarterly volatility.

• Operating income turned negative for four straight quarters from Q3 2025 through Q1 2026 after positive results in Q4 2024 and Q2 2025.

• Equity declined from $216M in Q1 2025 to $152M in Q1 2026, a $64M decrease over five quarters.

⚠ Operating cash flow turned deeply negative at -$17M in Q4 2025 and -$9M in Q1 2026 after strong positive flows.

⚠ Revenue pattern suggests lumpy contract-based business model with uncertain timing of future large quarters.

AI Insight: SIGA Ratio Trends

SIGA's profitability collapsed from 56.3% operating margin in Q2 2025 to -85.2% in Q1 2026, reflecting extreme quarterly volatility typical of biotech revenue cycles.

• Operating margin swung wildly from 70.1% in Q4 2024 to -32.0% in Q1 2025, then back to 56.3% in Q2 2025 before plunging to -85.2% in Q1 2026.

• Net profit margin turned deeply negative at -143.1% in Q4 2025 and -55.3% in Q1 2026 after reaching 43.7% in Q2 2025.

• ROE deteriorated from 67.8% in Q2 2025 to negative territory for three consecutive quarters through Q1 2026.

• ROIC plummeted from 87.3% in Q2 2025 to -14.0% in Q1 2026, marking four straight quarters of negative returns.

⚠ Extreme quarterly volatility suggests lumpy revenue recognition pattern that could continue creating unpredictable earnings swings.

⚠ TTM metrics show 22.0% operating margin despite recent losses, indicating potential for recovery if revenue normalizes.

Get alerted when SIGA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SIGA TECHNOLOGIES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SIGA

BlackRock, Inc.
$18.7M3,494,193 sh
DIMENSIONAL FUND ADVISORS LP
$14.5M2,702,724 sh
AltraVue Capital, LLC
$13.0M2,432,024 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.2M1,714,380 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$8.2M1,525,960 sh
AMERICAN CENTURY COMPANIES INC
$7.1M1,317,784 sh
GEODE CAPITAL MANAGEMENT, LLC
$7.0M1,315,545 sh
AQR CAPITAL MANAGEMENT LLC
$6.5M1,219,677 sh
STATE STREET CORP
$5.4M1,011,938 sh
FIRST WILSHIRE SECURITIES MANAGEMENT INC
$4.8M890,498 sh

Fund	Value	Shares
BlackRock, Inc.	$18.7M	3,494,193
DIMENSIONAL FUND ADVISORS LP	$14.5M	2,702,724
AltraVue Capital, LLC	$13.0M	2,432,024
VANGUARD CAPITAL MANAGEMENT LLC	$9.2M	1,714,380
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$8.2M	1,525,960
AMERICAN CENTURY COMPANIES INC	$7.1M	1,317,784
GEODE CAPITAL MANAGEMENT, LLC	$7.0M	1,315,545
AQR CAPITAL MANAGEMENT LLC	$6.5M	1,219,677
STATE STREET CORP	$5.4M	1,011,938
FIRST WILSHIRE SECURITIES MANAGEMENT INC	$4.8M	890,498

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SIGA on your watchlist

Track score changes the day SIGA TECHNOLOGIES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SIGA a good stock to buy?

13F Pro's AI-powered analysis of SIGA TECHNOLOGIES INC (SIGA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SIGA are available on the SIGA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SIGA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SIGA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SIGA TECHNOLOGIES INC's investment landscape.